Skip to main content
SpringerLink
Log in

Dysregulated Epigenetic Modifications in the Pathogenesis of NAFLD-HCC

  • Chapter
  • First Online:
Book cover Obesity, Fatty Liver and Liver Cancer

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1061))

Abstract

The pathogenesis of NAFLD is multi-faceted and mechanisms underlying the progression from simple steatosis to NASH have not been fully deciphered. The emerging field of epigenetics, an inheritable phenomenon capable of changing gene expression without altering DNA sequence, unveils a new perspective on the development of NAFLD and subsequent progression to HCC. In fact, numerous studies have highlighted the potential involvement of unhealthy daily habits such as physical inactivity and over-nutrition in the onset and development of NAFLD through epigenetic mechanisms. This chapter will discuss several epigenetic modulations including DNA methylation, histone modifications, functions of non-coding RNAs as well as RNA methylation implicated in the pathogenesis of NAFLD-HCC. On the basis of currently wealthy knowledge of DNA epigenetics, the rapidly growing field of RNA epigenetics will certainly drive forward a new avenue of research direction shedding light on the advancement of better diagnostics, prognostics and therapeutics in the coming era of precision medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263–73.

    Article  PubMed  CAS  Google Scholar 

  2. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155–61.

    Article  PubMed  CAS  Google Scholar 

  3. Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu Rev Pathol. 2016;11:451–96.

    Article  PubMed  CAS  Google Scholar 

  4. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112.

    Article  PubMed  CAS  Google Scholar 

  5. Sun C, Fan JG, Qiao L. Potential epigenetic mechanism in non-alcoholic fatty liver disease. Int J Mol Sci. 2015;16:5161–79.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol. 2014;7:221–39.

    PubMed  PubMed Central  Google Scholar 

  7. Lee JH, Friso S, Choi SW. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Forum Nutr. 2014;6:3303–25.

    Google Scholar 

  8. Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol. 2013;10:645–55.

    Article  PubMed  CAS  Google Scholar 

  9. Zilberman D, Henikoff S. Genome-wide analysis of DNA methylation patterns. Development. 2007;134:3959–65.

    Article  PubMed  CAS  Google Scholar 

  10. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333:1300–3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Park LK, Friso S, Choi SW. Nutritional influences on epigenetics and age-related disease. Proc Nutr Soc. 2012;71:75–83.

    Article  PubMed  CAS  Google Scholar 

  13. da Silva RP, Kelly KB, Al Rajabi A, Jacobs RL. Novel insights on interactions between folate and lipid metabolism. Biofactors. 2014;40:277–83.

    Article  PubMed  CAS  Google Scholar 

  14. Jacobs RL, Lingrell S, Zhao Y, Francis GA, Vance DE. Hepatic CTP:phosphocholine cytidylyltransferase-alpha is a critical predictor of plasma high density lipoprotein and very low density lipoprotein. J Biol Chem. 2008;283:2147–55.

    Article  PubMed  CAS  Google Scholar 

  15. Martinez-Chantar ML, Corrales FJ, Martinez-Cruz LA, Garcia-Trevijano ER, Huang ZZ, Chen L, et al. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J. 2002;16:1292–4.

    Article  PubMed  CAS  Google Scholar 

  16. Tryndyak VP, Han T, Muskhelishvili L, Fuscoe JC, Ross SA, Beland FA, et al. Coupling global methylation and gene expression profiles reveal key pathophysiological events in liver injury induced by a methyl-deficient diet. Mol Nutr Food Res. 2011;55:411–8.

    Article  PubMed  CAS  Google Scholar 

  17. Sookoian S, Puri P, Castano GO, Scian R, Mirshahi F, Sanyal AJ, et al. Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency. Liver Int. 2017;37:611–9.

    Article  PubMed  CAS  Google Scholar 

  18. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–18.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med. 2007;131:1728–34.

    PubMed  CAS  Google Scholar 

  20. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis. 1999;19:129–40.

    Article  PubMed  CAS  Google Scholar 

  21. Law JA, Jacobsen SE. Establishing, maintaining and modifying DNA methylation patterns in plants and animals. Nat Rev Genet. 2010;11:204–20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Pogribny IP, Tryndyak VP, Bagnyukova TV, Melnyk S, Montgomery B, Ross SA, et al. Hepatic epigenetic phenotype predetermines individual susceptibility to hepatic steatosis in mice fed a lipogenic methyl-deficient diet. J Hepatol. 2009;51:176–86.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Wu Y, Bu F, Yu H, Li W, Huang C, Meng X, et al. Methylation of Septin9 mediated by DNMT3a enhances hepatic stellate cells activation and liver fibrogenesis. Toxicol Appl Pharmacol. 2016;315:35–49.

    Article  PubMed  CAS  Google Scholar 

  24. Pirola CJ, Scian R, Gianotti TF, Dopazo H, Rohr C, Martino JS, et al. Epigenetic modifications in the biology of nonalcoholic fatty liver disease: the role of DNA Hydroxymethylation and TET proteins. Medicine (Baltimore). 2015;94:e1480.

    Article  CAS  Google Scholar 

  25. Murphy SK, Yang H, Moylan CA, Pang H, Dellinger A, Abdelmalek MF, et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:1076–87.

    Article  PubMed  CAS  Google Scholar 

  26. Zeybel M, Hardy T, Robinson SM, Fox C, Anstee QM, Ness T, et al. Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. Clin Epigenetics. 2015;7:25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  PubMed  CAS  Google Scholar 

  28. Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Mendez-Gonzalez J, et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology. 2015;61:1945–56.

    Article  PubMed  CAS  Google Scholar 

  29. Revill K, Wang T, Lachenmayer A, Kojima K, Harrington A, Li J, et al. Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology. 2013;145:1424–1435 e1421–1425.

    Article  PubMed  CAS  Google Scholar 

  30. Li H, Yang F, Gao B, Yu Z, Liu X, Xie F, et al. Hepatitis B virus infection in hepatocellular carcinoma tissues upregulates expression of DNA methyltransferases. Int J Clin Exp Med. 2015;8:4175–85.

    PubMed  PubMed Central  CAS  Google Scholar 

  31. Thienpont B, Steinbacher J, Zhao H, D'Anna F, Kuchnio A, Ploumakis A, et al. Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature. 2016;537:63–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Chen ZJ, Pikaard CS. Epigenetic silencing of RNA polymerase I transcription: a role for DNA methylation and histone modification in nucleolar dominance. Genes Dev. 1997;11:2124–36.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Gallego-Duran R, Romero-Gomez M. Epigenetic mechanisms in non-alcoholic fatty liver disease: an emerging field. World J Hepatol. 2015;7:2497–502.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J. 2008;22:3549–60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol. 2013;23:471–82.

    Article  PubMed  CAS  Google Scholar 

  36. Lee KK, Workman JL. Histone acetyltransferase complexes: one size doesn't fit all. Nat Rev Mol Cell Biol. 2007;8:284–95.

    Article  PubMed  CAS  Google Scholar 

  37. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci. 2001;114:2363–73.

    PubMed  CAS  Google Scholar 

  38. Bricambert J, Miranda J, Benhamed F, Girard J, Postic C, Dentin R. Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J Clin Invest. 2010;120:4316–31.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Jia YL, Xu M, Dou CW, Liu ZK, Xue YM, Yao BW, et al. P300/CBP-associated factor (PCAF) inhibits the growth of hepatocellular carcinoma by promoting cell autophagy. Cell Death Dis. 2016;7:e2400.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Feng D, Liu T, Sun Z, Bugge A, Mullican SE, Alenghat T, et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science. 2011;331:1315–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Bae HJ, Jung KH, Eun JW, Shen Q, Kim HS, Park SJ, et al. MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer. J Hepatol. 2015;63:408–19.

    Article  PubMed  CAS  Google Scholar 

  42. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004;73:417–35.

    Article  PubMed  CAS  Google Scholar 

  43. Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer. 2010;10:819–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Herranz D, Munoz-Martin M, Canamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010;1:3.

    Article  PubMed  CAS  Google Scholar 

  45. Liu L, Liu C, Zhang Q, Shen J, Zhang H, Shan J, et al. SIRT1-mediated transcriptional regulation of SOX2 is important for self-renewal of liver cancer stem cells. Hepatology. 2016;64:814–27.

    Article  PubMed  CAS  Google Scholar 

  46. Li Y, Xu S, Li J, Zheng L, Feng M, Wang X, et al. SIRT1 facilitates hepatocellular carcinoma metastasis by promoting PGC-1alpha-mediated mitochondrial biogenesis. Oncotarget. 2016;7:29255–74.

    PubMed  PubMed Central  Google Scholar 

  47. Chen J, Chan AW, To KF, Chen W, Zhang Z, Ren J, et al. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3beta/beta-catenin signaling. Hepatology. 2013;57:2287–98.

    Article  PubMed  CAS  Google Scholar 

  48. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010;17:41–52.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, Aouizerat B, et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell. 2011;44:177–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Rice JC, Briggs SD, Ueberheide B, Barber CM, Shabanowitz J, Hunt DF, et al. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell. 2003;12:1591–8.

    Article  PubMed  CAS  Google Scholar 

  51. Fei Q, Shang K, Zhang J, Chuai S, Kong D, Zhou T, et al. Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53. Nat Commun. 2015;6:8651.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Ueda K, Hayaishi O. ADP-ribosylation. Annu Rev Biochem. 1985;54:73–100.

    Article  PubMed  CAS  Google Scholar 

  53. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci. 2007;32:12–9.

    Article  PubMed  CAS  Google Scholar 

  54. Corda D, Di Girolamo M. Functional aspects of protein mono-ADP-ribosylation. EMBO J. 2003;22:1953–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Nomura F, Yaguchi M, Togawa A, Miyazaki M, Isobe K, Miyake M, et al. Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2000;15:529–35.

    Article  PubMed  CAS  Google Scholar 

  56. Lampiasi N, Umezawa K, Montalto G, Poly CM. (ADP-ribose) polymerase inhibition synergizes with the NF-kappaB inhibitor DHMEQ to kill hepatocellular carcinoma cells. Biochim Biophys Acta. 2014;1843:2662–73.

    Article  PubMed  CAS  Google Scholar 

  57. Verger A, Perdomo J, Crossley M. Modification with SUMO. A role in transcriptional regulation. EMBO Rep. 2003;4:137–42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Hay RT. SUMO: a history of modification. Mol Cell. 2005;18:1–12.

    Article  PubMed  CAS  Google Scholar 

  59. Muller S, Hoege C, Pyrowolakis G, Jentsch S. SUMO, ubiquitin’s mysterious cousin. Nat Rev Mol Cell Biol. 2001;2:202–10.

    Article  PubMed  CAS  Google Scholar 

  60. Yeh ET. SUMOylation and De-SUMOylation: wrestling with life’s processes. J Biol Chem. 2009;284:8223–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Shiio Y, Eisenman RN. Histone sumoylation is associated with transcriptional repression. Proc Natl Acad Sci U S A. 2003;100:13225–30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Jin ZL, Pei H, Xu YH, Yu J, Deng T. The SUMO-specific protease SENP5 controls DNA damage response and promotes tumorigenesis in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2016;20:3566–73.

    PubMed  Google Scholar 

  63. Liu J, Tao X, Zhang J, Wang P, Sha M, Ma Y, et al. Small ubiquitin-related modifier 1 is involved in hepatocellular carcinoma progression via mediating p65 nuclear translocation. Oncotarget. 2016;7:22206–18.

    PubMed  PubMed Central  Google Scholar 

  64. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81:145–66.

    Article  PubMed  CAS  Google Scholar 

  65. Chaudhuri K, Chatterjee R. MicroRNA detection and target prediction: integration of computational and experimental approaches. DNA Cell Biol. 2007;26:321–37.

    Article  PubMed  CAS  Google Scholar 

  66. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development. 2005;132:4653–62.

    Article  PubMed  CAS  Google Scholar 

  67. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol. 2006;13:1097–101.

    Article  PubMed  CAS  Google Scholar 

  68. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010;11:252–63.

    Article  PubMed  CAS  Google Scholar 

  69. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol. 2005;3:e85.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  70. Mraz M, Pospisilova S. MicroRNAs in chronic lymphocytic leukemia: from causality to associations and back. Expert Rev Hematol. 2012;5:579–81.

    Article  PubMed  CAS  Google Scholar 

  71. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119:586–93.

    Article  PubMed  CAS  Google Scholar 

  72. Sotiropoulou G, Pampalakis G, Lianidou E, Mourelatos Z. Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA. 2009;15:1443–61.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Yang L, Belaguli N, Berger DH. MicroRNA and colorectal cancer. World J Surg. 2009;33:638–46.

    Article  PubMed  Google Scholar 

  74. Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA profiling of prostate cancer. J Cancer. 2013;4:350–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699–707.

    Article  CAS  PubMed  Google Scholar 

  76. Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13:239–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Celikbilek M, Baskol M, Taheri S, Deniz K, Dogan S, Zararsiz G, et al. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol. 2014;6:613–20.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Lewis AP, Jopling CL. Regulation and biological function of the liver-specific miR-122. Biochem Soc Trans. 2010;38:1553–7.

    Article  PubMed  CAS  Google Scholar 

  79. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438:685–9.

    Article  PubMed  CAS  Google Scholar 

  80. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3:87–98.

    Article  PubMed  CAS  Google Scholar 

  81. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012;122:2884–97.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Csak T, Bala S, Lippai D, Satishchandran A, Catalano D, Kodys K, et al. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 2015;35:532–41.

    Article  PubMed  CAS  Google Scholar 

  83. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28:3526–36.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  84. Kishikawa T, Otsuka M, Tan PS, Ohno M, Sun X, Yoshikawa T, et al. Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine. Oncotarget. 2015;6:8339–52.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Boix L, Lopez-Oliva JM, Rhodes AC, Bruix J. Restoring mir122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through smad-independent TGF-beta pathway. Oncotarget. 2016;7:71309.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology. 2008;48:1810–20.

    Article  PubMed  CAS  Google Scholar 

  87. Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int. 2014;2014:741465.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Loyer X, Paradis V, Henique C, Vion AC, Colnot N, Guerin CL, et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARalpha expression. Gut. 2016;65:1882–94.

    Article  PubMed  CAS  Google Scholar 

  89. Vinciguerra M, Sgroi A, Veyrat-Durebex C, Rubbia-Brandt L, Buhler LH, Foti M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology. 2009;49:1176–84.

    Article  PubMed  CAS  Google Scholar 

  90. Zhang N, Duan WD, Leng JJ, Zhou L, Wang X, Xu YZ, et al. STAT3 regulates the migration and invasion of a stemlike subpopulation through microRNA21 and multiple targets in hepatocellular carcinoma. Oncol Rep. 2015;33:1493–8.

    Article  PubMed  CAS  Google Scholar 

  91. Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H, et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 2013;58:119–25.

    Article  PubMed  CAS  Google Scholar 

  92. Derdak Z, Villegas KA, Harb R, Wu AM, Sousa A, Wands JR. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol. 2013;58:785–91.

    Article  PubMed  CAS  Google Scholar 

  93. Xiao Z, Li CH, Chan SL, Xu F, Feng L, Wang Y, et al. A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma. Cancer Res. 2014;74:6236–47.

    Article  PubMed  CAS  Google Scholar 

  94. Hur W, Lee JH, Kim SW, Kim JH, Bae SH, Kim M, et al. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway. Int J Biochem Cell Biol. 2015;64:265–76.

    Article  PubMed  CAS  Google Scholar 

  95. Liu X, Zhang A, Xiang J, Lv Y, Zhang X. miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway. Oncol Rep. 2016;36:1385–92.

    Article  PubMed  CAS  Google Scholar 

  96. Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut. 2012;61:1600–9.

    Article  PubMed  CAS  Google Scholar 

  97. Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F, et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology. 2012;56:1025–33.

    Article  PubMed  CAS  Google Scholar 

  98. Hardy T, Mann DA. Epigenetics in liver disease: from biology to therapeutics. Gut. 2016;65:1895.

    Article  PubMed  CAS  Google Scholar 

  99. Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science. 2008;322:750–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  100. Chen G, Yu D, Nian X, Liu J, Koenig RJ, Xu B, et al. LncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase (ATGL). Sci Rep. 2016;6:35531.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  101. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007;132:330–42.

    Article  PubMed  CAS  Google Scholar 

  102. Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol. 2011;18:1243–50.

    Article  PubMed  Google Scholar 

  103. Fu WM, Zhu X, Wang WM, Lu YF, Hu BG, Wang H, et al. Hotair mediates hepatocarcinogenesis through suppressing miRNA-218 expression and activating P14 and P16 signaling. J Hepatol. 2015;63:886–95.

    Article  PubMed  CAS  Google Scholar 

  104. Malakar P, Shilo A, Mogilavsky A, Stein I, Pikarsky E, Nevo Y, et al. Long noncoding RNA MALAT1 promotes hepatocellular carcinoma development by SRSF1 up-regulation and mTOR activation. Cancer Res. 2017;77(5):1155–67.

    Article  PubMed  CAS  Google Scholar 

  105. Wu L, Candille SI, Choi Y, Xie D, Jiang L, Li-Pook-Than J, et al. Variation and genetic control of protein abundance in humans. Nature. 2013;499:79–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  106. Machnicka MA, Milanowska K, Osman Oglou O, Purta E, Kurkowska M, Olchowik A, et al. MODOMICS: a database of RNA modification pathways--2013 update. Nucleic Acids Res. 2013;41:D262–7.

    Article  PubMed  CAS  Google Scholar 

  107. Wei CM, Moss B. Methylated nucleotides block 5′-terminus of vaccinia virus messenger RNA. Proc Natl Acad Sci U S A. 1975;72:318–22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  108. Rottman FM, Desrosiers RC, Friderici K. Nucleotide methylation patterns in eukaryotic mRNA. Prog Nucleic Acid Res Mol Biol. 1976;19:21–38.

    Article  PubMed  CAS  Google Scholar 

  109. Cao G, Li HB, Yin Z, Flavell RA. Recent advances in dynamic m6A RNA modification. Open Biol. 2016;6:160003.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7:885–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  111. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell. 2012;149:1635–46.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  112. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201–6.

    Article  CAS  PubMed  Google Scholar 

  113. Batista PJ, Molinie B, Wang J, Qu K, Zhang J, Li L, et al. m(6)A RNA modification controls cell fate transition in mammalian embryonic stem cells. Cell Stem Cell. 2014;15:707–19.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  114. Bokar JA, Rath-Shambaugh ME, Ludwiczak R, Narayan P, Rottman F. Characterization and artial purification of mRNA N6-adenosine methyltransferase from HeLa cell nuclei. Internal mRNA methylation requires a multisubunit complex. J Biol Chem. 1994;269:17697–704.

    PubMed  CAS  Google Scholar 

  115. Bokar JA, Shambaugh ME, Polayes D, Matera AG, Purification RFM. cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA. 1997;3:1233–47.

    PubMed  PubMed Central  CAS  Google Scholar 

  116. Chen T, Hao YJ, Zhang Y, Li MM, Wang M, Han W, et al. m(6)A RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency. Cell Stem Cell. 2015;16:289–301.

    Article  PubMed  CAS  Google Scholar 

  117. Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10:93–5.

    Article  PubMed  CAS  Google Scholar 

  118. Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49:18–29.

    Article  PubMed  CAS  Google Scholar 

  119. Boissel S, Reish O, Proulx K, Kawagoe-Takaki H, Sedgwick B, Yeo GS, et al. Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations. Am J Hum Genet. 2009;85:106–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  120. Klungland A, Dahl JA. Dynamic RNA modifications in disease. Curr Opin Genet Dev. 2014;26:47–52.

    Article  PubMed  CAS  Google Scholar 

  121. Blanco S, Frye M. Role of RNA methyltransferases in tissue renewal and pathology. Curr Opin Cell Biol. 2014;31:1–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  122. Lim A, Zhou J, Sinha RA, Singh BK, Ghosh S, Lim KH, et al. Hepatic FTO expression is increased in NASH and its silencing attenuates palmitic acid-induced lipotoxicity. Biochem Biophys Res Commun. 2016;479:476–81.

    Article  PubMed  CAS  Google Scholar 

  123. Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen I, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m(6)A-demethylation of NANOG mRNA. Proc Natl Acad Sci U S A. 2016;113:E2047–56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  124. Lin S, Choe J, Du P, Triboulet R, Gregory RI. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 2016;62:335–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  125. Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH, Wang F, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N6 -methyladenosine-dependent primary MicroRNA processing. Hepatology. 2017;65:529–43.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Digestive Disease, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Fung Zhao

Authors
  1. Fung Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Digestive Disease and Department of Medicine & Therapeutics State Key Laboratory of Digestive Disease LKS Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Jun Yu

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zhao, F. (2018). Dysregulated Epigenetic Modifications in the Pathogenesis of NAFLD-HCC. In: Yu, J. (eds) Obesity, Fatty Liver and Liver Cancer. Advances in Experimental Medicine and Biology, vol 1061. Springer, Singapore. https://doi.org/10.1007/978-981-10-8684-7_7

Download citation

Publish with us

Policies and ethics

Search

Navigation